Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatment options, and Decoy Therapeutics, Inc., a privately held preclinical biopharmaceutical company engineering the next generation of peptide conjugate therapeutics, announce the signing of a definitive agreement under which Decoy Therapeutics will merge with a wholly-owned subsidiary of Salarius Pharmaceuticals, subject to the closing conditions set forth in the definitive agreement. The newly formed company will be named Decoy Therapeutics.
Read the full article: Salarius Pharmaceuticals and Decoy Therapeutics Announce Definitive Merger Agreement //
Source: https://www.globenewswire.com/news-release/2025/01/13/3008457/0/en/Salarius-Pharmaceuticals-and-Decoy-Therapeutics-Announce-Definitive-Merger-Agreement.html